Incorporating Drug‐Resistance Measurements into the Clinical Management of HIV‐1 Infection
Open Access
- 15 September 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 194 (s1) , S59-S64
Abstract
Testing for resistance to antiretrovirals is considered to be standard of care and is widely used in the management of human immunodeficiency virus (HIV)–infected persons. Despite the widespread use of resistance testing, the clinician still faces a number of challenges when applying these technologies in the optimal management of antiretroviral therapy. Both genotype and phenotype tests require interpretation, and available interpretative algorithms for genotypes and resistance cutoffs for phenotypes are incomplete and evolving. Even experts in HIV resistance do not completely agree in their interpretation of genotypes. Moreover, discordant results between genotypes and phenotypes are a common source of confusion when both tests are used to evaluate resistance in a patient. Finally, newer indicators, such as replication capacity, are clinically available and appear to have prognostic value, but how this in vitro measure should be used in the management of antiretroviral therapy remains to be fully defined.Keywords
This publication has 14 references indexed in Scilit:
- Accuracy, Precision, and Consistency of Expert HIV Type 1 Genotype Interpretation: An International Comparison (The GUESS Study)Clinical Infectious Diseases, 2005
- HIV-1 pol replication capacity predicts disease progressionAIDS, 2005
- Higher CD4+T Cell Counts Associated with Low ViralpolReplication Capacity among Treatment‐Naive Adults in Early HIV‐1 InfectionThe Journal of Infectious Diseases, 2004
- GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patientsAIDS, 2004
- Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and LamivudineThe Journal of Infectious Diseases, 2004
- Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA PanelClinical Infectious Diseases, 2003
- Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South AmericaNew England Journal of Medicine, 2003
- The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibilityAIDS, 2002
- Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European settingAIDS, 2001
- A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapyAIDS, 2000